Brought to you by 
Warner-Lambert helps develop Onyx-015 and armed viruses
17 Sep 2002
Executive Summary
Warner-Lambert will jointly develop Onyx Pharmaceuticals' Onyx-015, an adenovirus about to enter Phase III cancer trials, as well as two other anticancer viruses, one of them now in animal tests.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Warner-Lambert helps develop Onyx-015 and armed viruses
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice